• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EFNS 指南:阿尔茨海默病的诊断与管理。

EFNS guidelines for the diagnosis and management of Alzheimer's disease.

机构信息

Memory Disorders Clinic, Deartment of Neurology, Charles University in Prague, Second Faculty of Medicine and Motol Hospital, Prague, Czech Republic.

出版信息

Eur J Neurol. 2010 Oct;17(10):1236-48. doi: 10.1111/j.1468-1331.2010.03040.x.

DOI:10.1111/j.1468-1331.2010.03040.x
PMID:20831773
Abstract

BACKGROUND AND OBJECTIVES

In 2008 a task force was set up to develop a revision of the European Federation of the Neurological Societies (EFNS) guideline for the diagnosis and management of Alzheimer's disease (AD) and other disorders associated with dementia, published in early 2007. The aim of this revised international guideline was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with AD. Mild cognitive impairment and non-Alzheimer dementias are not included in this guideline.

METHODS

The task force working group reviewed evidence from original research articles, meta-analysis, and systematic reviews, published before May 2009. The evidence was classified and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided.

RESULTS

The recommendations for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of AD, behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers were all revised as compared with the previous EFNS guideline.

CONCLUSION

A number of new recommendations and good practice points are made, namely in CSF, neuropsychology, neuroimaging and reviewing non-evidence based therapies. The assessment, interpretation, and treatment of symptoms, disability, needs, and caregiver stress during the course of AD require the contribution of many different professionals. These professionals should adhere to these guideline to improve the diagnosis and management of AD.

摘要

背景与目的

2008 年,成立了一个工作组,旨在修订 2007 年初发表的欧洲神经病学会联盟(EFNS)关于阿尔茨海默病(AD)和其他与痴呆相关疾病的诊断和管理指南。该修订版国际指南的目的是为临床神经科医生、老年病学家、精神科医生和其他负责 AD 患者护理的专科医生提供一份同行评议的循证声明,以指导实践。本指南不包括轻度认知障碍和非阿尔茨海默型痴呆。

方法

工作组审查了 2009 年 5 月之前发表的原始研究文章、荟萃分析和系统评价的证据。根据 EFNS 指南对证据进行分类,并对共识建议进行分级(A、B 或 C)。在缺乏证据但有明确共识的情况下,提供了良好实践要点。

结果

与之前的 EFNS 指南相比,本指南对临床诊断、血液检查、神经心理学、神经影像学、脑电图、脑脊液(CSF)分析、基因检测、诊断披露、AD 治疗、痴呆的行为和心理症状、法律问题、咨询和支持照顾者的建议进行了修订。

结论

本指南提出了一些新的建议和良好实践要点,特别是在 CSF、神经心理学、神经影像学和审查非循证治疗方面。AD 病程中症状、残疾、需求和照顾者压力的评估、解释和治疗需要许多不同专业人员的参与。这些专业人员应遵循本指南,以改善 AD 的诊断和管理。

相似文献

1
EFNS guidelines for the diagnosis and management of Alzheimer's disease.EFNS 指南:阿尔茨海默病的诊断与管理。
Eur J Neurol. 2010 Oct;17(10):1236-48. doi: 10.1111/j.1468-1331.2010.03040.x.
2
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline.阿尔茨海默病及其他痴呆相关疾病的诊断与管理建议:欧洲神经科学联合会指南
Eur J Neurol. 2007 Jan;14(1):e1-26. doi: 10.1111/j.1468-1331.2006.01605.x.
3
EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia.EFNS-ENS 指南:痴呆相关疾病的诊断与管理。
Eur J Neurol. 2012 Sep;19(9):1159-79. doi: 10.1111/j.1468-1331.2012.03784.x.
4
EFNS task force: the use of neuroimaging in the diagnosis of dementia.EFNS 工作组:神经影像学在痴呆诊断中的应用。
Eur J Neurol. 2012 Dec;19(12):e131-40, 1487-501. doi: 10.1111/j.1468-1331.2012.03859.x. Epub 2012 Aug 20.
5
Alzheimer's disease. AMA Council on Scientific Affairs Reference Committee D.阿尔茨海默病。美国医学协会科学事务委员会参考委员会D。
J Okla State Med Assoc. 1998 Aug;91(5):298-306.
6
[European survey on current practice and disclosure of the diagnosis of Alzheimer's disease. A study based on caregiver's report].[欧洲关于阿尔茨海默病诊断的当前实践与披露情况的调查。一项基于照料者报告的研究]
Psychol Neuropsychiatr Vieil. 2003 Mar;1(1):45-55.
7
Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia.痴呆症的诊断与治疗:4. 轻度至中度痴呆症的管理方法
CMAJ. 2008 Oct 7;179(8):787-93. doi: 10.1503/cmaj.070803.
8
Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.阿尔茨海默病的诊断与治疗:过去、现在和未来的伦理问题。
Prog Neurobiol. 2013 Nov;110:102-13. doi: 10.1016/j.pneurobio.2013.01.003. Epub 2013 Apr 8.
9
Recommendations for best practices in the treatment of Alzheimer's disease in managed care.管理式医疗中阿尔茨海默病治疗的最佳实践建议。
Am J Geriatr Pharmacother. 2006;4 Suppl A:S9-S24; quiz S25-S28. doi: 10.1016/j.amjopharm.2006.10.001.
10
Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies.阿尔茨海默病及其他与痴呆相关疾病的诊断与管理。欧洲神经科医生的作用。欧洲神经科学学会联合会。
Eur J Neurol. 2000 Mar;7(2):133-44. doi: 10.1046/j.1468-1331.2000.00030.x.

引用本文的文献

1
Predicting Alzheimer's Disease Progression from Sparse Multimodal Data by NeuralODE Models.通过神经常微分方程模型从稀疏多模态数据预测阿尔茨海默病进展
bioRxiv. 2025 Aug 27:2025.08.26.672412. doi: 10.1101/2025.08.26.672412.
2
A Multimodal Multi-Stage Deep Learning Model for the Diagnosis of Alzheimer's Disease Using EEG Measurements.一种基于脑电图测量的用于阿尔茨海默病诊断的多模态多阶段深度学习模型。
Neurol Int. 2025 Jun 13;17(6):91. doi: 10.3390/neurolint17060091.
3
AI-based staging, causal hypothesis and progression of subjects at risk of Alzheimer's disease: a multicenter study.
基于人工智能的阿尔茨海默病高危受试者的分期、因果假设及病情进展:一项多中心研究
Front Neurol. 2025 May 19;16:1568086. doi: 10.3389/fneur.2025.1568086. eCollection 2025.
4
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study.载脂蛋白E ε4状态、化疗和内分泌治疗对乳腺癌幸存者认知功能的相互作用:CANTO-Cog纵向研究
Breast Cancer Res. 2025 Feb 19;27(1):25. doi: 10.1186/s13058-025-01974-2.
5
Reducing inference cost of Alzheimer's disease identification using an uncertainty-aware ensemble of uni-modal and multi-modal learners.使用单模态和多模态学习者的不确定性感知集成方法降低阿尔茨海默病识别的推理成本。
Sci Rep. 2025 Feb 14;15(1):5521. doi: 10.1038/s41598-025-86110-y.
6
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.阿尔茨海默病协会关于疑似阿尔茨海默病及相关疾病的诊断评估、检测、咨询与信息披露的临床实践指南(DETeCD - ADRD):专科护理建议执行摘要
Alzheimers Dement. 2025 Jan;21(1):e14337. doi: 10.1002/alz.14337. Epub 2024 Dec 23.
7
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.阿尔茨海默病协会关于疑似阿尔茨海默病及相关疾病的诊断评估、检测、咨询与信息披露的临床实践指南(DETeCD - ADRD):初级保健建议执行摘要
Alzheimers Dement. 2024 Dec 23. doi: 10.1002/alz.14333.
8
Non-adherence to antidementia medications and associated factors: a study of Spanish population-based registry data.抗痴呆药物治疗的不依从性及相关因素:基于西班牙人群登记数据的研究
Front Pharmacol. 2024 Nov 5;15:1425442. doi: 10.3389/fphar.2024.1425442. eCollection 2024.
9
Systemic determinants of brain health in ageing.大脑衰老的系统性决定因素。
Nat Rev Neurol. 2024 Nov;20(11):647-659. doi: 10.1038/s41582-024-01016-z. Epub 2024 Oct 7.
10
Olfaction and thyroid hormones in patients with subjective cognitive decline, non-amnestic and amnestic mild cognitive impairment.主观认知下降、非遗忘型和遗忘型轻度认知障碍患者的嗅觉与甲状腺激素
Wien Klin Wochenschr. 2025 Mar;137(5-6):172-181. doi: 10.1007/s00508-024-02431-4. Epub 2024 Sep 18.